SI
RARE icon

Sofinnova Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sofinnova Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.9M Buy
3,145,888
+3,062,588
+3,677% +$69M 2.5% 12
2025
Q4 		$1.92M Buy
+83,300
New +$2.74M 0.08% 53

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sofinnova Investments's RARE Position: Q1 2026 in Review

Sofinnova Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 3,677% in Q1 2026, buying an estimated $69M and bringing the position to 3,145,888 shares worth $65.9M. The position accounts for 2.5% of the portfolio, ranked #12.

Sofinnova Investments first reported a position in RARE in Q4 2025 and has held it in 2 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Sofinnova Investments held 3,145,888 shares of Ultragenyx Pharmaceutical worth $65.9M as of Q1 2026.
  • Sofinnova Investments bought 3,062,588 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $69M.
  • Ultragenyx Pharmaceutical made up 2.5% of Sofinnova Investments's portfolio in Q1 2026, its #12 holding.
  • Sofinnova Investments first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.